Ashley Chan

Ashley Chan joined the OncLive team as an assistant editor in 2025 after previously working on the CURE editorial team since 2023.

Email: achan@mjhlifesciences.com

Articles

Daratumumab-Based Regimens Yield Clinical Benefit Irrespective of Frailty Changes in Newly Diagnosed, Transplant-Ineligible Myeloma

September 18th 2025

Post hoc data demonstrated benefit with daratumumab-based regimens in newly diagnosed, transplant-ineligible myeloma, regardless of frailty changes.

Path Toward Accelerated Approval of RP1 in Advanced Melanoma Remains Unclear After FDA Type A Meeting

September 18th 2025

Replimune completed a Type A meeting with the FDA following a complete response letter for RP1 in advanced melanoma.

European Commission Green-Lights Vimseltinib for Symptomatic, Unresectable TGCT

September 18th 2025

Vimseltinib earned approval from the European Commission for the treatment of symptomatic, unresectable tenosynovial giant cell tumors.

Advances in Surgical Approaches and Targeted Therapies Highlight Progress in Uterine Cancer

September 18th 2025

John P. Diaz, MD, discusses the role of minimally invasive surgical approaches for the treatment of patients with uterine cancer.

Dr Gangat on Ruxolitinib as the Standard of Care in Myelofibrosis

September 18th 2025

Naseema Gangat, MBBS, discusses the JAK inhibitor ruxolitinib as the standard of care for the treatment of patients with myelofibrosis.

Dr Pal on the Rationale for Evaluating Atezolizumab in High-Risk Localized RCC

September 18th 2025

Sumanta Pal, MD, FASCO, explained the rationale for evaluating atezolizumab vs placebo for the treatment of patients with high-risk localized RCC.

Retifanlimab Displaces Chemo Alone as the Frontline Standard of Care in SCAC

September 17th 2025

Retifanlimab is the first and only immunotherapy agent to receive an indication for the frontline treatment of patients with advanced SCAC.

Ligufalimab Nets FDA Orphan Drug Designation in AML

September 16th 2025

Ligufalimab has been granted orphan drug designation by the FDA for the treatment of patients with AML.

FDA Grants Fast Track Designation to CRB-701 for Pretreated Recurrent or Metastatic HNSCC

September 16th 2025

The novel ADC CRB-701 was granted FDA fast track designation for the treatment of patients with recurrent or metastatic pretreated HNSCC.

Final CAPTIVATE Analysis Data Support Frontline Fixed-Duration Ibrutinib Plus Venetoclax in CLL/SLL

September 16th 2025

Paolo Ghia, MD, PhD, details the final analysis of the phase 2 CAPTIVATE study evaluating frontline ibrutinib/venetoclax in patients with CLL.

Dr Arora on the Associations Between Income/Race and MCL Survival Outcomes

September 15th 2025

Ruby Arora, MD, discusses a study investigating survival outcomes and sociodemographic disparities among patients with MCL from 2000 to 2021.

Dr Dorritie on the Use of Pirtobrutinib Following Prior BTK Inhibition in CLL

September 15th 2025

Kathleen A. Dorritie, MD, discusses data that inform the use of pirtobrutinib and liso-cel for the treatment of patients with chronic lymphocytic leukemia.

Dr Eroglu on the Role of Triplet vs Doublet Regimens in Melanoma With Symptomatic Brain Metastases

September 15th 2025

Zeynep Eroglu, MD, discusses the implications of using triplet vs doublet regimens in patients with melanoma who have symptomatic brain metastases.

Shield Blood Test Yields High Sensitivity, Specificity for CRC Screening in Expansion Cohort of Average-Risk Adults

September 12th 2025

The Shield blood-based CRC screening test demonstrated a sensitivity of 84% for detecting CRC with 90% specificity in an expanded cohort.

Evolving Surgical Strategies and the Role of Mirvetuximab Soravtansine Shape the Ovarian Cancer Treatment Paradigm

September 11th 2025

Ryan M. Kahn, MD, MHS, FACOG, discusses the evolution of surgical techniques and practice-changing treatments in the ovarian cancer treatment paradigm.

Dr Jacob on the FDA Approval of the Gemcitabine Intravesical System for NMIBC

September 11th 2025

Joseph Jacob, MD, MCR, discusses the FDA approval of the gemcitabine intravesical system for patients with BCG-unresponsive NMIBC with carcinoma in situ.

Second-Line Axi-Cel and Liso-Cel Lead as Standards of Care in LBCL

September 11th 2025

Supriya Gupta, MD, discussed the utility of axi-cel and liso-cel in real-world settings as second-line treatment in large B-cell lymphoma.

FLAURA-2 and HARMONi Trial Readouts Reinforce Importance of ‘Divide and Conquer’ Approach to Lung Cancer Care at WCLC 2025

September 11th 2025

Experts reflect on pivotal data, emerging agents, and highly anticipated trends in lung cancer during the IASLC 2025 World Conference on Lung Cancer.

Dr Kuykendall on Quality of Life Outcomes With Rusfertide in Polycythemia Vera

September 10th 2025

Andrew Kuykendall, MD, details the benefit of rusfertide regarding quality of life in patients with polycythemia vera compared with placebo.

Dr Necchi on the Design of the Phase 2 SURE-02 Study Assessing Pembrolizumab/Sacituzumab Govitecan in Muscle-Invasive Bladder Cancer

September 10th 2025

Andrea Necchi, MD, discusses the design of the SURE-02 study evaluating pembrolizumab plus sacituzumab govitecan in muscle-invasive bladder cancer.